BMS 986454
Alternative Names: BMS-986454Latest Information Update: 12 May 2026
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 27 Feb 2026 Phase-I clinical trials in Rheumatoid arthritis (Treatment-experienced) in India (unspecified route) (NCT07171983)
- 15 Sep 2025 Bristol-Myers Squibb plans a phase I trial for Rheumatoid arthritis in January 2026 (NCT07171983)
- 12 Jun 2024 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in United Kingdom (NCT06086886)